Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381
Phone: (281) 863 3000Website: http://www.lexpharma.com/Careers: www.lexpharma.com/careers
Latest news
- Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
27 July 2022 - Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
31 May 2022 - Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
28 February 2022 - Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes
30 December 2021 - Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
14 January 2021 - FDA Issues Complete Response Letter for Zynquista (sotagliflozin)
25 March 2019 - FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
17 January 2019 - FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
22 May 2018 - Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes
26 March 2018
Drugs Associated with Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Xermelo
Generic name: telotristat Drug class: miscellaneous GI agents |
1 review | 10 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
